par
FDA says no to Amgen’s Parsabiv
August 25, 2016Research and Development, Sales and Marketing Amgen, FDA, par
Amgen has announced that the US Food and Drug Administration (FDA) has issued a complete response letter rejecting Parsabiv (etelcalcetide) …
NICE approves Sutent but rejects rivals
February 4, 2009Sales and Marketing NICE, par
NICE has approved Pfizer's Sutent but rejected three other treatments for kidney cancer. The decision is one of the first …
Green light for kidney cancer drugs in Wales
January 26, 2009Sales and Marketing NHS, par, rcc
Kidney cancer patients in Wales are to gain access to the four new drugs that are still denied on the …
Sutent to be first to benefit from NICE reform
January 20, 2009Sales and Marketing NICE, par
Sutent and other rival treatments for renal cell carcinoma look set to be the first drugs to benefit from reforms …
Postcode prescribing to persist warn MPs
January 20, 2009NHS, par
The draft NHS Constitution will not help end the postcode lottery surrounding access to drugs, the Health Select Committee has …
Revlimid talks confirm shift in approach to pricing
January 20, 2009Sales and Marketing NICE, par
Celgene is in negotiations to agree a deal to make its cancer drug Revlimid more affordable to the NHS and …
UK pharma to lose
January 8, 2009Sales and Marketing ABPI, NHS, par
The UK pharmaceutical industry stands to lose £225 million in annual profits under its new pricing agreement with the government. …
PMCPA cautions on the way new prices are promoted
January 7, 2009Sales and Marketing par, reg
UK pharma companies have been warned not to mislead doctors about new lower prices of medicines. Code of Practice regulator …
NICE makes end-of-life drugs more available
January 6, 2009Sales and Marketing NICE, par
High-cost drugs that extend the lives of terminally ill patients will be more readily approved for NHS use, thanks to …
SMC criticises PPRS prescribing incentives
December 5, 2008Sales and Marketing NICE, par
The government move to incentivise doctors for the prescription of new innovative medicines has been criticised by the Scottish Medicines …
Flexible pricing PPRS hailed as a ‘landmark’ deal
November 21, 2008Sales and Marketing ABPI, par
The future of UK medicines could be revolutionised by a new deal that contains two pioneering measures on flexible prices …
Government and pharma reach PPRS deal
November 19, 2008Sales and Marketing ABPI, par
The UK government has agreed a new flexible pricing deal with the industry, in which companies can raise the price …
UK set for new flexible drug pricing, says Johnson
November 14, 2008Sales and Marketing NHS, par
The government is working with the pharma industry on new 'flexible pricing' arrangements, even though revisions to the existing PPRS …
Government delays PPRS to maximise savings
November 12, 2008Sales and Marketing ABPI, par
The PPRS deal agreed in principle this summer has been now thrown into confusion by government, with its launch at …
Pharma and NICE must end games of ‘one-upmanship’
November 10, 2008Sales and Marketing NHS, par
Patient groups are calling on a pharmaceutical company to reach a compromise with NICE over a bone marrow cancer drug. …
Latest content
FibroFind appoints Lee Borthwick as CEO
